An open-label, phase 2 trial of Nanatinostat in combination with valganciclovir in patients with Epstein-Barr virus-positive (EBV+) relapsed/refractory lymphomas (NAVAL-1)
EBV Associated Lymphoma
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Leong Tze Shin
CONTACT
SC: Leong Tze Shin
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Genetic Variation Associated with Bortezomib Induced Peripheral Neuropathy in Adult Multiple Myeloma Patients (Investigator initiated study) (IMR Bortezomib)
Multiple Myeloma
Beacon Hospital
PRINCIPAL INVESTIGATOR
Dr Tengku Ahmad Hidayat
+603 7787 2993
drtengkuhidayat@gmail.com
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Relapsed or Refractory Multiple Myeloma
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
TAN SUI KEAT
CONTACT
SC: Siti Nurfazlina Binti Mohd Roslan
CRC: 042225767 / 762
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations (BELLWAVE-008)
Chronic Lymphocytic Leukemia
Ampang Hospital
PRINCIPAL INVESTIGATOR
TAN SEN MUI
tan.sen.mui@moh.gov.my
03-42896156
CONTACT
SC: Nabila Azirah
Sultanah Aminah Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Boo Yang Liang
CONTACT
SC: Siti Masnirah
CRC: 07 – 356 5000 ext: 2408
A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Follicular Lymphoma and Marginal Zone Lymphoma
Ampang Hospital
PRINCIPAL INVESTIGATOR
TAN SEN MUI
tan.sen.mui@moh.gov.my
03-42896156
CONTACT
SC: NORFARAHIN BADRUL HISHAM
Sultanah Aminah Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Boo Yang Liang
CONTACT
SC: Rainianti Daman, Hafizah
CRC: 07 – 356 5000 ext: 2408
A phase 3, randomized, open label study evaluating the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, versus standard of care therapy in participants with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (OLYMPIA-4)
B-cell non-Hodgkin lymphoma
Ampang Hospital
PRINCIPAL INVESTIGATOR
TAN SEN MUI
tan.sen.mui@moh.gov.my
03-42896156
CONTACT
SC: Wan Nor Atikah Binti Che Wan Mohd Rozali
Sultanah Aminah Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Boo Yang Liang
CONTACT
SC: Komathy A/P Selvaraj
Queen Elizabeth Hospital
PRINCIPAL INVESTIGATOR
LILY WONG LEE LEE
CONTACT
SC: Merrin Suih